ROCKET PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
RCKT$2.45-3.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 2024 and
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $163,635 | $55,904 |
| Investments | 208,701 | 317,271 |
| Prepaid expenses and other current assets | 5,847 | 5,047 |
| Total current assets | 378,183 | 378,222 |
| Property and equipment, net | 36,786 | 39,172 |
| Goodwill | 39,154 | 39,154 |
| Intangible assets | 25,150 | 25,150 |
| Restricted cash | 1,362 | 1,372 |
| Deposits | 529 | 533 |
| Investments | - | 34,320 |
| Operating lease right-of-use assets, net | 4,173 | 3,901 |
| Finance lease right-of-use asset, net | 42,363 | 44,517 |
| Total assets | $527,700 | $566,341 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $37,827 | $45,789 |
| Operating lease liabilities, current | 1,001 | 925 |
| Finance lease liability, current | 1,856 | 1,791 |
| Total current liabilities | 40,684 | 48,505 |
| Operating lease liabilities, non-current | 3,258 | 2,973 |
| Finance lease liability, non-current | 19,383 | 19,353 |
| Other liabilities | 1,141 | 2,936 |
| Total liabilities | 64,466 | 73,767 |
| Commitments and contingencies (Note 14) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.01 par value, authorized 5,000,000 shares: | - | - |
| Series A convertible preferred stock; 300,000 shares designated; 0 shares issued and outstanding | - | - |
| Series B convertible preferred stock; 300,000 shares designated; 0 shares issued and outstanding | - | - |
| Common stock, $0.01 par value, 180,000,000 shares authorized; 106,453,818 and 90,282,267 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 1,065 | 903 |
| Additional paid-in capital | 1,680,219 | 1,450,722 |
| Accumulated other comprehensive income | 66 | 319 |
| Accumulated deficit | (1,218,116) | (959,370) |
| Total stockholders' equity | 463,234 | 492,574 |
| Total liabilities and stockholders' equity | $527,700 | $566,341 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.